查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1598686

三叉神經痛治療藥物市場：按產品，按最終用戶 - 全球預測 2025-2030

Trigeminal Neuralgia Therapeutics Market by Product (Drug, Surgery), End-user (Ambulatory Surgery Centers, Hospital & Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年三叉神經痛治療市值為2.4295億美元，預計到2024年將達到2.6217億美元，複合年成長率為8.00%，預計到2030年將達到4.1655億美元。

三叉神經痛治療市場範圍包括旨在管理和治療影響臉部三叉神經的嚴重慢性疼痛的各種成分。它的定義是抗驚厥藥物和肌肉鬆弛劑等醫療干預措施，也強調了微血管減壓手術和射頻熱損傷等創新治療方案。需要這些治療方法是因為三叉神經痛使人衰弱，影響患者的生活品質，需要有效的疼痛管理策略來緩解頻繁的嚴重面部疼痛。疼痛管理範圍從急性疼痛緩解到長期疼痛管理，最終用途主要在醫院、神經科科診所和居家醫療機構。關鍵的成長要素包括醫療技術的進步、意識和診斷率的提高以及對個人化醫療的更多關注，為相關人員提供了重要的機會。神經調節技術和生技藥品的發展進步為潛在投資機會提供了沃土，鼓勵公司轉向適應性和個人化治療解決方案。然而，市場成長也面臨挑戰，例如治療成本上升、現有藥物的副作用以及由於準確診斷困難而導致治療延遲等。此外，患者數量相對較少可能會阻礙大型製藥公司的大量投資並限制市場擴張。儘管存在這些挑戰，但可以透過提高現有藥物的療效、最大限度地減少副作用和探索尚未探索的基因治療途徑來刺激創新。這項見解強調了產業參與者需要投資於全面的研究和開發舉措，並促進與學術研究機構的合作，以克服現有治療障礙的新治療途徑。市場的性質是高度專業化的，並由患者對有效和微創治療的需求所驅動。

主要市場統計
基準年[2023] 2.4295億美元
預測年份 [2024] 2.6217 億美元
預測年份 [2030] 41655萬美元
複合年成長率（%） 8.00%

市場動態：快速發展的三叉神經痛治療市場的關鍵市場洞察

三叉神經痛治療藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 人口老化導致神經痛發生率增加
    • 政府努力提高人們對神經疼痛治療產品的認知
  • 市場限制因素
    • 神經痛治療高成本
  • 市場機會
    • 技術進步將消除對藥物和手術的需求
    • 新興經濟體外科和藥物治療的發展
  • 市場挑戰
    • 藥物的持續副作用

波特五力：駕馭三叉神經痛藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解三叉神經痛治療藥物市場的外在影響

外部宏觀環境因素在塑造三叉神經痛治療藥物市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解三叉神經痛治療藥物市場競爭狀況

三叉神經痛治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣三叉神經痛治療藥物市場供應商的績效評估

FPNV 定位矩陣是評估三叉神經痛治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，繪製三叉神經痛治療藥物市場的成功之路

對三叉神經痛治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 隨著年齡的成長，神經痛的發生率增加
      • 政府努力提高人們對神經疼痛治療產品的認知
    • 抑制因素
      • 治療神經痛費用高
    • 機會
      • 技術進步將消除對藥物和手術的需求
      • 新興經濟體外科和藥物治療的發展
    • 任務
      • 藥物的持續副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 三叉神經痛治療藥物市場：依產品

  • 藥品
    • 抗驚厥藥
    • 三環抗憂鬱藥物
  • 外科手術
    • 微血管減壓手術
    • 射頻燒傷治療
    • 立體放射線手術

第7章 三叉神經痛治療藥物市場：依最終使用者分類

  • 門診手術中心
  • 醫院/診所

第8章北美、南美三叉神經痛治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區三叉神經痛治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東、非洲三叉神經痛治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AMBOSS GmbH
  • Biogen, Inc.
  • Cadila Pharmaceuticals Limited
  • Capnia, Inc.
  • Cephalon A/S
  • Danaher Corporation
  • Glenmark Pharmaceuticals Limited
  • GSK plc
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • LGM Pharma, LLC
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
Product Code: MRR-FB6C9E793020

The Trigeminal Neuralgia Therapeutics Market was valued at USD 242.95 million in 2023, expected to reach USD 262.17 million in 2024, and is projected to grow at a CAGR of 8.00%, to USD 416.55 million by 2030.

The scope of the market for Trigeminal Neuralgia Therapeutics encompasses a wide array of factors aimed at managing and treating this severe chronic pain condition affecting the trigeminal nerve in the face. Defined by pharmaceutical interventions like anticonvulsants and muscle relaxants, innovative therapeutic options such as microvascular decompression and radiofrequency thermal lesioning are also noteworthy. The necessity of these therapeutics stems from the debilitating nature of trigeminal neuralgia, impacting patients' quality of life and requiring effective pain management strategies to mitigate frequent bouts of intense facial pain. Applications range from acute pain relief to long-term pain management, primarily serving end-use domains such as hospitals, specialized neurological clinics, and home healthcare set-ups. Key growth influencers include advances in medical technology, growing awareness and diagnosis rates, and an increased focus on personalized medicine, providing significant opportunities for stakeholders. The ongoing development in neuromodulation techniques and biologics presents a fertile ground for potential investment opportunities, urging companies to pivot towards adaptive and personalized therapeutic solutions. Nonetheless, market growth is challenged by limitations posed by high treatment costs and side effects associated with existing medications, along with the difficulty in diagnosing the condition accurately, which can delay treatment. Furthermore, a relatively small patient population can deter substantial investment from key pharmaceutical players, limiting market expansion. Despite these challenges, innovation can thrive in improving existing drug efficacy, minimizing side effects, or researching the unexplored path of gene therapies. This insight underscores the need for industry players to channel investment into comprehensive R&D initiatives and foster collaborations with academic research institutions, targeted at novel treatment pathways to overcome existing therapeutic barriers. The nature of the market is highly specialized and driven by patient demands for effective and less invasive treatments, with an anticipated trend towards custom-tailored therapeutic regimens in the coming years.

KEY MARKET STATISTICS
Base Year [2023] USD 242.95 million
Estimated Year [2024] USD 262.17 million
Forecast Year [2030] USD 416.55 million
CAGR (%) 8.00%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Trigeminal Neuralgia Therapeutics Market

The Trigeminal Neuralgia Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of neuralgia due to the rise in the aging population
    • Government initiatives to spread awareness regarding neuralgia treatment products
  • Market Restraints
    • High-cost associated with the treatment of neuralgia
  • Market Opportunities
    • Technological advancement eliminates the need for drugs and surgery
    • Developing surgical and pharmacological treatment in developing economies
  • Market Challenges
    • Persistent side effects from medications

Porter's Five Forces: A Strategic Tool for Navigating the Trigeminal Neuralgia Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Trigeminal Neuralgia Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Trigeminal Neuralgia Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Trigeminal Neuralgia Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Trigeminal Neuralgia Therapeutics Market

A detailed market share analysis in the Trigeminal Neuralgia Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Trigeminal Neuralgia Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Trigeminal Neuralgia Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Trigeminal Neuralgia Therapeutics Market

A strategic analysis of the Trigeminal Neuralgia Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Trigeminal Neuralgia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AMBOSS GmbH, Biogen, Inc., Cadila Pharmaceuticals Limited, Capnia, Inc., Cephalon A/S, Danaher Corporation, Glenmark Pharmaceuticals Limited, GSK plc, H. Lundbeck A/S, Johnson & Johnson Services, Inc., LGM Pharma, LLC, Lupin Limited, Novartis AG, and Pfizer Inc..

Market Segmentation & Coverage

This research report categorizes the Trigeminal Neuralgia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Drug and Surgery. The Drug is further studied across Anticonvulsant Medicines and Tricyclic Antidepressants. The Surgery is further studied across Microvascular Decompression, Radiofrequency Thermal Lesioning, and Stereotactic Radiosurgery.
  • Based on End-user, market is studied across Ambulatory Surgery Centers and Hospital & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of neuralgia due to the rise in the aging population
      • 5.1.1.2. Government initiatives to spread awareness regarding neuralgia treatment products
    • 5.1.2. Restraints
      • 5.1.2.1. High-cost associated with the treatment of neuralgia
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement eliminates the need for drugs and surgery
      • 5.1.3.2. Developing surgical and pharmacological treatment in developing economies
    • 5.1.4. Challenges
      • 5.1.4.1. Persistent side effects from medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Trigeminal Neuralgia Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Drug
    • 6.2.1. Anticonvulsant Medicines
    • 6.2.2. Tricyclic Antidepressants
  • 6.3. Surgery
    • 6.3.1. Microvascular Decompression
    • 6.3.2. Radiofrequency Thermal Lesioning
    • 6.3.3. Stereotactic Radiosurgery

7. Trigeminal Neuralgia Therapeutics Market, by End-user

  • 7.1. Introduction
  • 7.2. Ambulatory Surgery Centers
  • 7.3. Hospital & Clinics

8. Americas Trigeminal Neuralgia Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Trigeminal Neuralgia Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Trigeminal Neuralgia Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AMBOSS GmbH
  • 2. Biogen, Inc.
  • 3. Cadila Pharmaceuticals Limited
  • 4. Capnia, Inc.
  • 5. Cephalon A/S
  • 6. Danaher Corporation
  • 7. Glenmark Pharmaceuticals Limited
  • 8. GSK plc
  • 9. H. Lundbeck A/S
  • 10. Johnson & Johnson Services, Inc.
  • 11. LGM Pharma, LLC
  • 12. Lupin Limited
  • 13. Novartis AG
  • 14. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. TRIGEMINAL NEURALGIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. TRIGEMINAL NEURALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TRIGEMINAL NEURALGIA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANT MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY MICROVASCULAR DECOMPRESSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY RADIOFREQUENCY THERMAL LESIONING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. TRIGEMINAL NEURALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. TRIGEMINAL NEURALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023